Falk Nimmerjahn

22PUBLICATIONS
71CO-AUTHORS
Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 02, 2025
Macrophages foster anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction.

Kathrin Fuchs, Elisabetta D'Avanzo, Isabell Armstark

|Sep 28, 2024
Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies.

Marjan Hematianlarki, Falk Nimmerjahn

|Jul 17, 2024
Functional Fc receptors are crucial in antibody-mediated protection against cytomegalovirus.

Anna Bootz, Nina Reuter, Falk Nimmerjahn

|Apr 23, 2024
Fcγ-Receptor-Independent Controlled Activation of CD40 Canonical Signaling by Novel Therapeutic Antibodies for Cancer Therapy.

Karsten Beckmann, Carmen Reitinger, Xianglei Yan

|Aug 23, 2023
Publisher Correction: Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy.

Falk Nimmerjahn, Gestur Vidarsson, Mark S Cragg

|Jul 20, 2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

Markus Haake, Beatrice Haack, Tina Schäfer

Pageof 4

Frequent Collaborators

3 joint publications

Gestur Vidarsson

2 joint publications

Gerhard Krönke

2 joint publications

Diana Dudziak

1 joint publications

Harald Schuhwerk